The device is still waiting for US FDA approval, but is planned to be shipped from June 2024.
Dubbed a “multiscope,” the $250 device will tell you how warm (or not) you’re feeling, measure your blood oxygenation, run a one-lead ECG and even act as a digital stethoscope. Put this to your chest, and you can listen to the sounds your chest is making, or send the file to your physician for further analysis.
I have to say that compared to Fitbit (bought out by Google), Withings does appear to be innovating on the smartwatch, smart scale, and other health devices on a regular basis.
So, it will be interesting to see what the testing shows once the various reviewers have had a chance to test this device. There is nothing groundbreaking per se, but it is a compact and convenient device, and it is always useful to be able to have automated readings over time to determine trends.
The big question will be whether it has any relevancy as a telemedicine device. It could help doctors for the evaluation of conditions such as asthma or COPD. But their website does state that the BeamO has not been clinically/medically validated yet. The plan is to clinically validate the device and obtain CE marking and FDA clearance to bring BeamO to market as a medical device.